10 Worst Performing Mid Cap Stocks to Buy According to Analysts
Market analysts are increasingly highlighting mid-cap stocks as a potentially attractive investment opportunity, particularly in the current economic climate.
Viking Therapeutics Inc. (VKTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 1,485,079 | $59,759,579 | +1% | 0.01% |
| 2. | Braidwell LP Alex Karnal | 1,479,666 | $59,541,760 | +28% | 1.76% |
| 3. | 1,286,500 | $51,768,760 | -1% | 0% | |
| 4. | Perceptive Advisors Joseph Edelman | 995,894 | $40,074,775 | -42% | 1.1% |
| 5. | Balyasny Asset Management Dmitry Balyasny | 860,449 | $34,624,468 | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.15 | 1,240 | 1,240 | 2025-03-31 | Filing | ||
| $24.15 | 1,240 | 1,240 | 2025-03-31 | Filing | ||
| $2.47 | 45,000 | Director | 111,250 | 2022-05-02 | Filing | |
| $5.69 | 20,000 | Director | 66,250 | 2021-06-10 | Filing | |
| $9.82 | 9,500 | Director | 9,500 | 2018-05-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.32 | 19,000 | 2,366,570 | 2025-01-06 | Filing | ||
| $42.68 | 175,490 | 2,385,570 | 2025-01-06 | Filing | ||
| $43.32 | 5,100 | 374,134 | 2025-01-06 | Filing | ||
| $42.69 | 49,115 | 379,234 | 2025-01-06 | Filing | ||
| $43.32 | 4,700 | 165,259 | 2025-01-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 129,195 | $3,120,019 | 0% | |
| 2. | 117,769 | $2,844,122 | 2.64% | |
| 3. | 39,652 | $957,594 | 0.03% | |
| 4. | 23,800 | $574,770 | 0.02% | |
| 5. | 21,148 | $510,729 | 0.02% |
News See All
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
15 Stocks That Took a Nosedive in January
Historically, the S&P 500's performance in January sets the pace for the rest of the year.
Jim Cramer's Thoughts on These 7 Stocks
Jim Cramer, the host of Mad Money, recently revisited one of his core investment principles: "Nobody ever made a dime panicking." He emphasized that, no matter how many times he has shared this advice...
Jim Cramer’s Lightning Rounds: 9 Stocks in Focus
Jim Cramer, the host of Mad Money, recently expressed his concerns about the uncertain economic outlook for 2025, particularly in relation to corporate earnings and the stock market's expectations for...
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
12 Best Multibagger Stocks to Buy Right Now
The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs.
10 Stocks That Will Make You Rich In 2025
Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock market in 2025.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Billionaire Hedge Funds
